Omeros | OMER - Net Income


Omeros reported $-32.23M in Net Income for its fiscal quarter ending in September of 2024.





Net Income Change Date
Adma Biologics USD 49.38M 12.95M Dec/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Cytokinetics USD -183.03M 123.15M Dec/2025
Gilead Sciences USD 2.18B 869M Dec/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Immunic USD -24.37M 2.99M Sep/2024
Insmed USD -328.48M 41.54M Dec/2025
Knight Therapeutics CAD -3.79M 8.83M Sep/2025
MacroGenics USD -14.16M 30.98M Dec/2025
Omeros USD -32.23M 23.81M Sep/2024
Pacira USD 1.64M 3.8M Dec/2025
Pfizer USD -1.65B 5.19B Dec/2025
Rockwell Medical USD 343K 2.07M Jun/2024
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sarepta Therapeutics USD -412.23M 232.28M Dec/2025
United Therapeutics USD 364.3M 25.6M Dec/2025
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025
Xoma USD -17.24M 33.23M Sep/2024